Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Navitoclax Consolidation and Maintenance in High-risk T-ALL Prior to and Post Allogeneic Transplantation
NCT05054465Phase 2Not yet recruiting
- Sponsor
- Israel Medical Association
- Start
- Oct 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, navitoclax in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), mixed phenotype acute leukemia (MPAL), sponsored by Israel Medical Association. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
venetoclaxnavitoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT05054465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054465.